Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn's disease
Source: SeekingAlpha
2026-02-17 06:15:51 ET
Read the full article on Seeking Alpha
For further details see:
Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease
Banco Santander S.A. Sponsored ADR
NASDAQ: SAN
SAN Trading
6.27% G/L:
$11.605 Last:
15,249,186 Volume:
$11.50 Open:
SAN Latest News
February 03, 2026 01:38:00 pm
Webster Financial Corporation Enters Into Merger Agreement With Banco Santander, S.A. for $12.3 Billion
SAN Stock Data
$212,542,521,684
14,572,031,202
2.7%
312
N/A
Banking
Finance
ES
Boadilla del Monte
